



Regd. Office : 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

Factory : Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

Contact No. : +91 9820201063 / 8080333319 / 8411879521

Email : influxhealthtech@gmail.com/ influxhealthcare1@gmail.com

Website : www.influxhealthtech.com

CIN : U24299MH2020PLC346825

April 21, 2026

To,
Listing Department,
National Stock Exchange Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai-400 051

Scrip Code – INFLUX

Dear Sir/Mam,

Sub.: Business Update for the Quarter Ended March 31, 2026 (Q4FY26)

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Business Update – Q4FY26

Capacity Expansion, Innovation & Market Leadership Driving Value Creation

Influx Healthtech Limited concluded FY26 on a strong note, marking a transformative year defined by aggressive capacity expansion, advanced technology adoption, and strategic diversification across high-growth verticals. The Company continued its evolution from a traditional CDMO into an innovation-led, full-spectrum manufacturing partner, with investments across nutraceuticals, functional beverages, pet nutrition, and healthy snacking.

Q4FY26 Highlights

1. Robust Operational Performance:

The quarter and full year witnessed robust operational performance, supported by healthy year-on-year growth across key manufacturing verticals.

- Product mix improved significantly, driven by product innovation in specialty formats including liposomal delivery systems, MMTc (Multi Mini Tablet in Capsule), and Capsule-in-Capsule & Pellet Technologies.
- Margin profiles improved by focusing on operational cost rationalisation and high margin formats.
- Performance was driven by:
 - Higher utilisation across nutraceutical, cosmetic, and veterinary manufacturing lines.
 - Successful commercialisation of new clinical nutrition and functional wellness formats.

- Repeat orders from long-standing clients and continued onboarding of D2C wellness brands and clinical nutrition startups.
- Strong traction in the protein and functional bar segment, with long-term production commitment secured from Avolt Brand (~24 lakh bars).

2. Capacity & Technology Expansion:

The Company executed significant capex investments during the quarter and full year, funded entirely through internal accruals (~₹5 Cr+), reflecting strong cash flow generation and disciplined capital allocation:

- **Quick Snap Machine Commissioned:** Entry into innovative single-dose delivery formats, enhancing portfolio differentiation and premium product offerings.
- **Liquid Gel Sachet Machine Installed:** Expands capabilities in fast-absorbing nutraceutical formats, targeting the on-the-go consumer and OTC wellness market.
- **3-Track Blister Machine Installed:** Significant increase in blister packing throughput, improving operational efficiency and reducing turnaround time.
- **Auto Coater Machine Booked:** Ensures superior coating quality, consistency, and faster processing.
- **Auto Powder Filling Lines Added:** Increased automation and capacity for protein, nutraceutical, and wellness powders.

Advanced Production Lines (Booked / FAT Completed):

- **Pet Food Line – 1,000 kg/hr (FAT Completed):** Major scale-up in pet nutrition manufacturing, strengthening leadership in the veterinary and pet supplement CDMO space.
- **Additional Bar Production Line Booked:** Expands capacity for protein and functional bars to support increasing client demand.

3. Product Innovation & R&D:

The Company continued to invest in science-backed, differentiated delivery formats during the year:

- **Liposomal Product Range Introduced:** High bioavailability delivery systems positioning the Company in the premium, science-backed nutraceutical segment.
- **MMTC (Multi Mini Tablet in Capsule) Developed:** Advanced multi-release delivery format enhancing product differentiation for clients.
- **Capsule-in-Capsule & Pellet Technologies Developed:** Controlled and targeted release formulations expanding customisation capabilities for global clients.

4. Business Expansion & New Entity:

- **Incorporation of 100% Subsidiary – OLAHEY WELLNESS PVT LTD.:** Focused on beverages and healthy snacking, representing a strategic move towards brand-building and B2C opportunities. OLAHEY complements the core CDMO business with forward integration into consumer-facing categories.

5. Regulatory & Global Expansion:

- **Tanzania Audit Successfully Cleared:** Approval received for international operations, strengthening export credentials and the Company's global regulatory compliance footprint.

6. Outlook – FY27 and Beyond:

The management remains confident in sustaining execution momentum into FY27, driven by:

- Commercial rollout of products and lines developed and commissioned during FY26.
- Improved contribution from innovation-led SKUs, specialty formats, and high-margin differentiated categories.
- **FY27 Strategy:** Positioned as a "scale + innovation" year, focusing on higher wallet share from existing customers, entry into complex premium categories, and selective B2C expansion through OLAHEY Wellness Pvt Ltd.
- Continued expansion into **Clinical & Functional Nutrition, Cosmetic Innovation, and Pet Nutrition.**

Strategic Focus Areas:

- **Functional Beverages & Healthy Snacking:** Via OLAHEY Wellness Pvt Ltd. and new beverage and bar production lines.
- **Pet Nutrition:** Strengthening CDMO leadership in veterinary and pet supplement manufacturing.
- **High-Margin Differentiated Formats:** Liposomal, MMTC, retort, and RTD formats driving premium revenue mix.
- **Global Compliance & Export Readiness:** Tanzania approval as a stepping stone to broader international markets.
- **Financial Discipline:** Capex funded through internal accruals, reducing dependency on IPO funds.

The above information is subject to limited review / audit by the Statutory Auditors of the Company. The Company will continue to keep the stock exchanges informed of all material developments in compliance with applicable regulations.



Regd. Office : 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

Factory : Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

Contact No. : +91 9820201063 / 8080333319 / 8411879521

Email : influxhealthtech@gmail.com/ influxhealthcare1@gmail.com

Website : www.influxhealthtech.com

CIN : U24299MH2020PLC346825

We request you to take the above information on record.

Thanking you,
For Influx Healthtech Limited,

Munir Abdul Ganee Chandniwala
Managing Director
DIN: 08459582

For further information, please contact



Company

Influx Healthtech Limited

Mr. Ashish Shah, CFO

cs@influxhealthtech.com

Investor relations consultants

Capital Bridge Advisory Service Private Limited

Mr. Raj Shah, CFA

raj@capbridge.in

+91 99259 11296

Mr. Hrishit Jhaveri, CFA

hrishit@capbridge.in

+91 90999 94345